Company · founded 2004
PAI Life Sciences (United States)
Seattle, United States
- Citations, last 5 years
- 228
- Works, last 5 years
- 31
- h-index
- 34
- Scientists listed
- 0
- Grants since 2016
- 27
Grants received
2024–2025 · research · R41
Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield
Sean Alex Gray · PAI Life Sciences (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Evaluation of a Next Generation SchistoShield Vaccine
Sean Alex Gray · PAI Life Sciences (United States) · funded by National Institutes of Health
2022–2024 · contract · N43
LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS
Darrick Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2021–2022 · research · R43
Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
Darrick Albert Carter · PAI Life Sciences (United States) · funded by Centers for Disease Control and Prevention
2020–2023 · research · Global Health
PAI Life Sciences Inc. - to support the production of the SchistoShield vaccine for use in early human clinical studies in USA and Africa
PAI Life Sciences (United States) · funded by Bill and Melinda Gates Foundation
2020–2022 · research · R21
Developing a Screen for New Adjuvants to Enhance RNA Vaccines
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2020–2023 · research · R21
Developing a Screen for New Adjuvants to Enhance RNA Vaccines
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2023 · research · R44
A Vaccine for Lymphatic Filariasis, LFGuard™
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Process Development for a Lymphatic Filariasis Vaccine, (LFGuard™)
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2023 · research · R44
A Vaccine for Lymphatic Filariasis, LFGuard™
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2023 · research · R44
A Vaccine for Lymphatic Filariasis, LFGuard™
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2022 · contract · N44
Phase II - Development of a Prophylactic Onchocerciasis Vaccine
Darrick Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2026 · research · R44
A Vaccine for Lymphatic Filariasis, LFGuard™
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2020 · contract · N43
A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant
Amit Khandhar · PAI Life Sciences (United States) · funded by National Institutes of Health
2019–2027 · research · R44
A Vaccine for Lymphatic Filariasis, LFGuard™
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine
Sean Alex Gray · PAI Life Sciences (United States) · funded by National Institutes of Health
2017–2018 · research · R41
CruziScreen, a recombinant antigen-based screening test for Chagas disease
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2017–2018 · research · R43
Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus
Dan Thomas Stinchcomb · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2022 · research · R44
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2018 · contract · N43
DEVELOPMENT OF A PROPHYLACTIC ONCHOCERCIASIS VACCINE
Darrick Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2021 · research · R44
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2017 · research · R43
A recombinant protein that increases engraftment of hematopoietic stem cells
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2018 · contract · N43
COMBINING PARASITE AND VECTOR COMPONENTS FOR DEVELOPMENT OF A LEISHMANIA VACCINE
Rhea Coler · PAI Life Sciences (United States) · funded by National Institutes of Health
2016–2017 · research · R43
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2013–2023 · research · R44
A Vaccine for Schistosomiasis, "SchistoShield"
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2013–2023 · research · R44
A Vaccine for Schistosomiasis, "SchistoShield"
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health
2013–2025 · research · R44
A Vaccine for Schistosomiasis, "SchistoShield"
Darrick Albert Carter · PAI Life Sciences (United States) · funded by National Institutes of Health